蜜花在炎症性肠道疾病中的新兴作用
Peter Muro1, Caihong Jing2, Zhihan Zhao1
1Department of Laboratory Medicine, The Affiliated People's Hospital, Jiangsu University, Zhenjiang, Jiangsu, China.
Frontiers in nutrition
|April 14, 2025
概括
蜜是一种传统的中医药,显示出治疗炎症性肠病 (IBD) 的前景. 它的生物活性化合物具有抗炎和抗氧化功效,解决了当前IBD疗法的局限性.
科学领域:
- 药理学和中国传统医学
- 胃肠病学 胃肠病学
- 自然产品化学 自然产品化学
背景情况:
- 炎症性肠病 (IBD),包括克罗恩病 (CD) 和性结肠炎 (UC),具有高复发率和全球发病率的慢性挑战.
- 目前的IBD疗法存在局限性,需要开发新的,安全和有效的治疗方法.
- 传统中医 (TCM) 为药物发现提供了宝贵的资源,因为它具有多样化的生物活性,低毒性和最小的副作用.
研究的目的:
- 审查花 (Lonicera japonica) 和其生物活性代谢物作为炎症性肠病 (IBD) 的治疗策略的潜力.
- 探索Lonicera japonica在治疗IBD中的潜在机制.
- 突出特定的蜜代谢物对IBD预防和治疗的治疗益处.
主要方法:
- 关于Lonicera japonica及其在炎症性肠病 (IBD) 治疗中的应用的科学研究的文献综述.
- 对花花中存在的生物活性代谢物研究的分析.
- 检查蜂及其化合物的抗炎,免疫调节和抗氧化特性.
主要成果:
- 蜜 (Lonicera japonica) 含有生物活性代谢物,包括丁,素,氨酸,原酸 (CGA),咖啡酸 (CA) 和氨酸.
- 这些代谢物在治疗炎症性肠病 (IBD) 中具有显著的治疗益处.
- 蜜表现出抗炎,免疫系统调节和抗氧化品质,支持其在IBD管理中的作用.
结论:
- 蜜花及其生物活性代谢物是预防和治疗炎症性肠病 (IBD) 的有希望的天然产品候选者.
- 对Lonicera japonica的基本机制和临床应用的进一步研究是有必要的.
- 蜜为IBD患者提供了潜在的替代或补充疗法,这些患者寻求更安全,更有效的选择.
相关概念视频
01:28Inflammatory Response
1.6K
An inflammatory response is a localized, nonspecific immune reaction that occurs when a tissue is injured. It is characterized by redness, swelling, heat, and pain, which are commonly called the cardinal signs and symptoms of inflammation. Inflammation can sometimes result in a loss of function.
Inflammation can be triggered by various stimuli, such as impact, abrasion, chemical irritation, infections, and extreme hot or cold temperatures. These can damage cells and connective tissue fibers,...
Inflammation can be triggered by various stimuli, such as impact, abrasion, chemical irritation, infections, and extreme hot or cold temperatures. These can damage cells and connective tissue fibers,...
1.6K
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
100
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
100
01:30Inflammatory Bowel Disease II: Crohn's Disease
129
Introduction
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
129
01:30Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
246
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
246
01:29Inflammatory Bowel Disease IV: Pharmacological Management
80
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
80
01:17Chronic Bowel Disorders: Introduction
325
Chronic bowel diseases are a group of long-term conditions affecting the digestive tract, characterized by inflammation and damage to the gut lining. These conditions primarily include irritable bowel syndrome and inflammatory bowel disease.
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
325